Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation - PubMed (original) (raw)

Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation

Leslie A Mitchell. J Med Microbiol. 1999 Dec.

Abstract

Antibody (AMI) and cell-mediated (CMI) immunity to rubella virus (RV) were evaluated in healthy adolescent males (n = 11) and females (n = 28) undergoing routine reimmunisation with RA27/3 strain RV as a component of measles-mumps-rubella (MMR) vaccine. Blood samples were collected just before and at 2, 4 and 10 weeks after MMR. While there were no sex differences before MMR and at week 10 after vaccination, levels of specific IgG determined by whole RV enzyme immunoassay were found to be significantly higher in males at weeks 2 and 4, suggesting brisker onset of recall AMI. Analysis of RV protein-specific IgG by immunoblot assays also revealed that while there were no notable sex differences in the distribution of E1-specific antibodies, more males produced E2-specific antibodies whereas more females produced C-specific antibodies after immunisation. Analysis of CMI with whole inactivated RV and a panel of RV synthetic peptides in lymphocyte proliferation assays revealed a brisker onset of CMI in males which paralleled that observed for AMI. The numbers of RV antigens recognised by males were significantly higher at weeks 2 and 4. Also, mean and median stimulation indices measured at weeks 2 and 4 for certain peptides, including two known to contain overlapping antibody neutralisation domains and T-cell epitopes, E1(213-239) and E1(254-285), were also found to be significantly higher in male subjects. These observations suggest that there are hormonal influences on RV-specific immunity which might result in differential handling of RV and, hence, may partially explain why females are more predisposed to adverse outcomes of rubella infection and immunisation.

PubMed Disclaimer

Similar articles

• [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
  Zäch K, Nicoara C, Germann D, Matter L. Zäch K, et al. Schweiz Med Wochenschr. 1998 Apr 25;128(17):649-57. Schweiz Med Wochenschr. 1998. PMID: 9622837 German.
• Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
  Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE. Watson BM, et al. J Infect Dis. 1996 Mar;173(3):731-4. doi: 10.1093/infdis/173.3.731. J Infect Dis. 1996. PMID: 8627041 Clinical Trial.
• Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
  Johnson CE, Kumar ML, Whitwell JK, Staehle BO, Rome LP, Dinakar C, Hurni W, Nalin DR. Johnson CE, et al. Pediatr Infect Dis J. 1996 Aug;15(8):687-92. doi: 10.1097/00006454-199608000-00010. Pediatr Infect Dis J. 1996. PMID: 8858673
• Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.
  Davidkin I, Peltola H, Leinikki P, Valle M. Davidkin I, et al. Vaccine. 2000 Jul 15;18(27):3106-12. doi: 10.1016/s0264-410x(00)00139-0. Vaccine. 2000. PMID: 10856790
• [Duration of immunity and occurrence of secondary vaccine failure following vaccination against measles, mumps and rubella].
  Trier H, Rønne T. Trier H, et al. Ugeskr Laeger. 1992 Jul 13;154(29):2008-13. Ugeskr Laeger. 1992. PMID: 1509566 Review. Danish.

Cited by

• Immune Cells, Gut Microbiota, and Vaccines: A Gender Perspective.
  Rio P, Caldarelli M, Chiantore M, Ocarino F, Candelli M, Gasbarrini A, Gambassi G, Cianci R. Rio P, et al. Cells. 2024 Mar 17;13(6):526. doi: 10.3390/cells13060526. Cells. 2024. PMID: 38534370 Free PMC article. Review.
• Sex-Differential and Non-specific Effects of Vaccines Over the Life Course.
  St Clair LA, Chaulagain S, Klein SL, Benn CS, Flanagan KL. St Clair LA, et al. Curr Top Microbiol Immunol. 2023;441:225-251. doi: 10.1007/978-3-031-35139-6_9. Curr Top Microbiol Immunol. 2023. PMID: 37695431 Free PMC article. Review.
• Sex differences in the percentage of IRF5 positive B cells are associated with higher production of TNF-α in women in response to TLR9 in humans.
  Beisel C, Jordan-Paiz A, Köllmann S, Ahrenstorf AE, Padoan B, Barkhausen T, Addo MM, Altfeld M. Beisel C, et al. Biol Sex Differ. 2023 Feb 22;14(1):11. doi: 10.1186/s13293-023-00495-x. Biol Sex Differ. 2023. PMID: 36814288 Free PMC article.
• Seroprevalence and durability of rubella virus antibodies in a highly immunized population.
  Crooke SN, Haralambieva IH, Grill DE, Ovsyannikova IG, Kennedy RB, Poland GA. Crooke SN, et al. Vaccine. 2019 Jun 27;37(29):3876-3882. doi: 10.1016/j.vaccine.2019.05.049. Epub 2019 May 21. Vaccine. 2019. PMID: 31126859 Free PMC article.
• Factors That Influence the Immune Response to Vaccination.
  Zimmermann P, Curtis N. Zimmermann P, et al. Clin Microbiol Rev. 2019 Mar 13;32(2):e00084-18. doi: 10.1128/CMR.00084-18. Print 2019 Mar 20. Clin Microbiol Rev. 2019. PMID: 30867162 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ingenta plc

• Molecular Biology Databases

  • Immune Epitope Database and Analysis Resource